Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BALCHEM CORPBCPC · Entity 3839 | Retired Director | January 03, 2017 | January 06, 2017 |
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director | September 14, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BALCHEM CORP
Report date January 03, 2017 · Filed January 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,068 |
Reported balance
After 2017-01-03 transaction · row 1
1 source rowRow 1 · 2017-01-03 · Sale · Disposed 747 · Balance 25,068 F1: On February 23, 2016, the Company granted 1,808 restricted shares under the Company's Long Term Incentive Program. The stock was subject to a repurchase option in favor of the Issuer and to restrictions on transfer until it vested on January 1, 2017. 747 of the 1,808 shares that vested January 1, 2017 were withheld to cover taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 23, 2016, the Company granted 1,808 restricted shares under the Company's Long Term Incentive Program. The stock was subject to a repurchase option in favor of the Issuer and to restrictions on transfer until it vested on January 1, 2017. 747 of the 1,808 shares that vested January 1, 2017 were withheld to cover taxes.
Krystal Biotech, Inc.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $340.03 · Expires 2036-09-13 | Direct | 1,187 |
Reported balance
After 2026-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 1,187 · Balance 1,187 F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 471 |
Reported balance
After 2026-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-14 · Grant · Acquired 471 · Balance 471 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 00:05 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 471 | $0.00 | $0.00 |
DisclosureSEC source: 0001209059-26-000008 · wk-form4_1789603516.xml · derivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471 Underlying: Common Stock · 471 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. F3 · derivative.expiration_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 00:05 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 1,187 | $0.00 Strike: $340.03 | $0.00 |
DisclosureSEC source: 0001209059-26-000008 · wk-form4_1789603516.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,187 Underlying: Common Stock · 1,187 shares Expires 2036-09-13 F1 · derivative.exercise_date: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 40 | $333.23 | $13,329.20 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 9 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,095 | $331.43 | $1,025,786.06 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 8 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,040 F8 · price: The transaction was executed in multiple trades ranging from $331.02 to $331.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,896 | $330.36 | $1,617,422.00 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 7 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,135 F7 · price: The transaction was executed in multiple trades ranging from $330 to $330.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,428 | $329.60 | $2,448,279.94 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 6 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,031 F6 · price: The transaction was executed in multiple trades ranging from $329.01 to $329.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,687 | $328.52 | $554,205.14 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 5 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,459 F5 · price: The transaction was executed in multiple trades ranging from $328.01 to $328.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,226 | $327.39 | $1,710,960.52 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 4 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,146 F4 · price: The transaction was executed in multiple trades ranging from $327 to $327.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,287 | $326.60 | $746,940.60 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 3 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,372 F3 · price: The transaction was executed in multiple trades ranging from $326.04 to $326.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 341 | $325.60 | $111,029.09 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,659 F2 · price: The transaction was executed in multiple trades ranging from $325 to $325.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 22:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GiftCommon Stock | 3,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001209059-26-000006 · wk-form4_1786746156.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · kind: Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,950 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001209059-26-000003 · wk-form4_1771892075.xml · derivative · entry 4 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,950 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested ratably over a four-year period beginning on June 1, 2018. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,834 | $262.10 | $2,839,591.40 |
DisclosureSEC source: 0001209059-26-000003 · wk-form4_1771892075.xml · nonDerivative · entry 3 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,691 F1 · price: Multiple lots for the same price for this transaction have been combined. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,116 | $260.49 | $2,114,102.75 |
DisclosureSEC source: 0001209059-26-000003 · wk-form4_1771892075.xml · nonDerivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,525 Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 18,950 | $8.79 | $166,570.50 |
DisclosureSEC source: 0001209059-26-000003 · wk-form4_1771892075.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 22:04 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $137.46 | $0.00 |
DisclosureSEC source: 0001209059-25-000003 · wk-form4_1751321048.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period. Read SEC document |
| September 13, 2024 Filed Sep 13, 2024 21:41 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209059-24-000004 · wk-form4_1726263692.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,691 F1 · kind: Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 23:21 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $183.64 | $0.00 |
DisclosureSEC source: 0001209059-24-000002 · wk-form4_1719876067.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $117.40 | $0.00 |
DisclosureSEC source: 0001711279-23-000055 · wk-form4_1688416054.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2033-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:05 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 40,000 | $83.25 | $3,329,972.00 |
DisclosureSEC source: 0001711279-23-000012 · wf-form4_167779471000119.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,691 F1 · price: The transaction was executed in multiple trades ranging from $82.245 to $83.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001711279-22-000040 · wf-form4_165670651988931.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 15:39 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $68.00 | $0.00 |
DisclosureSEC source: 0001711279-21-000022 · wf-form4_162524036673173.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2031-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2021 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2020 Filed Aug 8, 2020 00:43 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $41.42 | $0.00 |
DisclosureSEC source: 0000899243-20-021815 · doc4.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2030-06-29 F1 · derivative.exercise_date: The options were awarded on June 30, 2020 and vest in equal monthly tranches over a one-year period. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:53 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0001209191-18-035197 · doc4.xml · derivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-31 F1 · derivative.exercise_date: The options were awarded on May 31, 2018 and vest monthly over a one-year period. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | ConversionSeries A Convertible Preferred Stock · Derivative | 123,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-17-000365 · edgar.xml · derivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 123,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.exercise_date: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.expiration_date: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | ConversionCommon Stock | 123,691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000925421-17-000365 · edgar.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A convertible preferred stock converted on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 21:41 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 747 | $83.26 | $62,195.22 |
DisclosureSEC source: 0001140361-17-000993 · doc1.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Retired Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,068 F1 · shares: On February 23, 2016, the Company granted 1,808 restricted shares under the Company's Long Term Incentive Program. The stock was subject to a repurchase option in favor of the Issuer and to restrictions on transfer until it vested on January 1, 2017. 747 of the 1,808 shares that vested January 1, 2017 were withheld to cover taxes. Read SEC document |
| December 08, 2016 Filed Dec 8, 2016 22:39 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,562 | $86.15 | $737,623.15 |
DisclosureSEC source: 0001140361-16-089131 · doc1.xml · nonDerivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,007 F1 · shares: Sale of shares pursuant to Rule 10b5-1. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 22:39 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,200 | $83.15 | $681,830.82 |
DisclosureSEC source: 0001140361-16-089131 · doc1.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,569 F1 · shares: Sale of shares pursuant to Rule 10b5-1. F2 · balance_after: Amount adjusted to reflect current number of shares in Mr Ross's 401(k) account Read SEC document |
| November 16, 2016 Filed Nov 16, 2016 22:14 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,200 | $77.88 | $638,625.02 |
DisclosureSEC source: 0001140361-16-086979 · doc1.xml · nonDerivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,762 F1 · shares: Sale of shares pursuant to Rule 10b5-1. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 22:14 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,200 | $77.81 | $638,073.98 |
DisclosureSEC source: 0001140361-16-086979 · doc1.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,962 F1 · shares: Sale of shares pursuant to Rule 10b5-1. F2 · balance_after: Amount adjusted to reflect current number of shares in Mr Ross's 401(k) account Read SEC document |
| October 07, 2016 Filed Oct 7, 2016 20:53 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,200 | $78.51 | $643,794.30 |
DisclosureSEC source: 0001140361-16-082304 · doc1.xml · nonDerivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,048 F1 · shares: Sale of shares pursuant to Rule 10b5-1. Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 20:53 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,200 | $78.62 | $644,684.00 |
DisclosureSEC source: 0001140361-16-082304 · doc1.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,248 F1 · shares: Sale of shares pursuant to Rule 10b5-1. Read SEC document |
| September 09, 2016 Filed Sep 9, 2016 21:12 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,200 | $67.40 | $552,643.10 |
DisclosureSEC source: 0001140361-16-079381 · doc1.xml · nonDerivative · entry 2 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,448 F1 · shares: Sale of shares pursuant to Rule 10b5-1. Read SEC document |
| September 08, 2016 Filed Sep 9, 2016 21:12 UTC | BALCHEM CORP BCPC · Entity 3839 | SaleCommon Stock | 8,200 | $69.12 | $566,820.90 |
DisclosureSEC source: 0001140361-16-079381 · doc1.xml · nonDerivative · entry 1 ROSSI DINO A · CIK 0001209059 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,648 F1 · shares: Sale of shares pursuant to Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.